logo BDSP

Base documentaire


  1. New and emerging therapies for Parkinson disease.

    Article - En anglais

    Few neurological disorders have been more successful in introducing novel therapies than Parkinson disease (PD).

    However, despite enormous progress, many challenges remain.

    Although levodopa is still the most effective drug in the symptomatic treatment of PD, adverse effects, particularly motor fluctuations and dyskinesias, limit its usefulness.

    Furthermore, there is a growing concern about the escalating cost of PD treatment : the cost-benefit aspect of the novel approaches must be balanced against the advantages of long-term experience with established treatments.

    Mots-clés Pascal : Parkinson maladie, Analyse avantage coût, Neuroprotecteur, Traitement, Chimiothérapie, Homme, Antiparkinsonien, Système nerveux pathologie, Système nerveux central pathologie, Encéphale pathologie, Extrapyramidal syndrome, Maladie dégénérative, Economie santé

    Mots-clés Pascal anglais : Parkinson disease, Cost benefit analysis, Neuroprotective agent, Treatment, Chemotherapy, Human, Antiparkinson agent, Nervous system diseases, Central nervous system disease, Cerebral disorder, Extrapyramidal syndrome, Degenerative disease, Health economy

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0375980

    Code Inist : 002B02B06. Création : 22/03/2000.